ROS1 and non-small cell lung carcinoma: However, its therapeutic efficacy was compromised in patients who received prior chemotherapy[33,34], indicating that chemotherapy-resistant NSCLC patients exhibit poor efficacy of crizotinib despite having altered/aberrant activation of known targets, ALK, c-MET/HGFR, or ROS1, suggesting the exploration of alternative treatment options.